Your Messages Inbox
Your Article Summary
See Latest ArticlesNplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Amgen, 02/09/09
Amgen announced that the European Commission has granted marketing authorisation for Nplate for the treatment of splenectomised adult chronic immune thrombocytopenic purpura patients who are refractory to other treatments. Nplate may be considered as second line treatment for adult non-splenectomised ITP patients where surgery is contra-indicated.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
US FDA approves SEROQUEL XR for add-on treatment of Major Depressive Disorder
AstraZeneca, 12/07/09
FDA Approves Initiation of Clinical Studies in the U.S. for T2000, Taros Proprietary Non-Sedating Barbiturate Compound
Taro Pharmaceuticals USA, 12/07/09
Article Search
Sponsor